Sanofi Pasteur

In 2004, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division of Sanofi-Aventis Group,[3][4] changed its name to Sanofi Pasteur.[5] In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable.[6] Doctors Without Borders said that it would take two years to develop a similar antivenom, and that existing stocks would run out in June 2016.[6] One of the vaccines ordered by the Netherlands for the mass anti-coronavirus vaccination programme in 2021, seems not to work well on elderly people and the deveoplment of the vaccine will face delays.[7]

In July 2020, Sanofi Pasteur announced that it would begin phase three testing of a COVID-19 vaccine in several countries, including Mexico, and that the cost would be US $7 to $10 per dose.[8] If data are positive, a global phase 3 study could start in Q2 2021. If the vaccine meets clinical requirements on safety and effictiveness, approved by regulatory authorities, a vaccine can expected in the fourth quarter of 2021.[9]

Sanofi Pasteur

• 2012 net sales: €3,897 million (+5.7% over 2011)
• Staff: nearly 13,000 employees worldwide
• More than 1 billion doses of vaccines produced yearly to immunize more than 500 million people in the world
• Largest product range available, against 20 infectious diseases
• More than €1 million invested every day in R&D
• Nearly €2 billion invested in the last 5 years in production infrastructures.
• Headquarters: Lyon, France
• 14 production and/or R&D sites located in:
  • Marcy-l'Étoile and Val-de-Reuil, France
  • Swiftwater, Pennsylvania (Sanofi Pasteur's United States headquarters),[15] Cambridge, Massachusetts and Canton, Massachusetts, Orlando, Florida and Rockville, Maryland, United States
  • Toronto, Ontario, Canada
  • Pilar, Buenos Aires Province, Argentina
  • Shenzhen, China
  • Hyderabad, India
  • Ocoyoacac, Mexico
  • Chachoengsao, Thailand
  • Neuville-sur-Saône, France[16]

the listing below is for named vaccines; Sanofi Pasteur produces many vaccines which do not bear trade names[17]

• Cancer vaccines
  • bladder cancer: TheraCys[18]
• Coronavirus vaccines
  • A COVID-19 vaccine is under development by the French pharmaceutical and the British pharmaceutical company GlaxoSmithKline.[19] Advanced clinical trials of the vaccine were delayed in December 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021.[20]
• Dengue vaccines
  • Dengvaxia, approved in 18 countries[21][22]
• DPT vaccines[17][23]
  • Adacel
  • Daptacel
  • Tripedia (Trepedia), discontinued, last shipped in 2012[24]
• Haemophilus influenzae type b vaccines
  • ActHIB[17][23][25]
• Hepatitis A vaccines
  • Avaxim 160 U[25] (or just Avaxim)[26]
• Hepatitis B vaccines[25]
  • Genhevac B Pasteur
  • Hbvaxpro (5, 10 and 40 μg)
• Influenza vaccines
  • Addigrip[26]
  • Fluzone[23] (standard; without preservatives; pediatric dose without preservatives)[26]
  • Sandovac[26]
  • Vaxigrip[25][26]
• Japanese encephalitis virus vaccines
  • JE-VAX[18]
• Measles vaccines
  • Rouvax[25]
• Meningococcal vaccines
  • Menactra, the first meningococcal vaccine approved for use in infants[18][23][27]
  • Menomune-A/C/Y/W-135[18]
  • Vaccin Meningococcique A+C[25]
• MMR vaccines
  • M-M-RVaxPro[25]
• Pneumonia vaccines
  • Pneumo 23[25][26]
• Polio vaccines
  • Imovax Polio[25]
  • Ipol[23]
  • Polio Salk[26]
• Rabies vaccines
  • IMOVAX RABIES[18] (Imovax)[23]
  • Imogam Rabies-HT, rabies immune globulin[18]
  • Vaccin Rabique Pasteur[25]
• Rubella vaccines
  • Rudivax[25]
• Smallpox vaccines
  • ACAM 2000[23]
• Tetanus vaccines
  • Vaccin Tetanique Pasteur[25]
• Tuberculosis vaccines
  • Mycobax[23]
  • Tubersol[18]
  • Vaccin Bcg Ssi[25]
• Typhoid fever vaccines
  • Typhim Vi[17][25][23]
• Yellow fever vaccines
  • Stamaril[25][26]
  • YF-VAX[17][23][26]
• Diphtheria and tetanus combined vaccines
  • DECAVAC[23]
  • dT reduct[26]
  • D. T. Vax[25]
• Diphtheria, tetanus and polio combined vaccines
  • Revaxis[25]
• DPT, haemophilus combined vaccines
  • TriHIBit, a booster vaccine, with DPT and haemophilus influenzae type b vaccines[18]
• DPT, polio combined vaccines
  • Repevax[25][26]
• DPT, haemophilus, polio combined vaccines
  • Pentacel[17][23]
  • Pentavac[25]
• DPT, haemophilus, polio, hepatitis B combined vaccines
  • Hexavac[26]
• Hepatitis A, typhoid fever combined vaccines
  • Tyavax[25]

In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold.[28] The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain,[29] such as a tuberculosis vaccine ImmuCYST, a BCG immunotherapeutic, a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits.[28] The resulting closure of the plant for over two years resulted in shortages of bladder cancer and tuberculosis vaccines.[30] On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG.[31]

Sanofi Pasteur is the founding sponsor of Sanofi Biogenius Canada (SBC), a national, biotechnology-focused science competition for Canadian high school and CEGEP students. Those selected for the SBC work with local mentors, giving students hands-on research experience in a professional lab setting. Participants compile their results and present their findings at regional competitions. Cash prizes are awarded and regional winners advance to the National stage, where they vie for the top spot and the chance to compete in the International BioGENEius Challenge, held at the prestigious BIO International Convention – the largest biotechnology event in the world.

The Philippine Department of Health began in 2016 a programme in three regions to vaccinate schoolchildren against dengue fever, using Dengvaxia supplied by Sanofi Pasteur. On 29 November 2017, Sanofi issued a caution stating that new analysis had shown that those vaccinated who had not previously been infected with dengue ran a greater risk of infection causing severe symptoms. On 1 December 2017, the Philippine DOH placed the programme on hold, pending review. Over 700,000 people had received at least one vaccination at that point.[32][33] Since the announcement by Sanofi, at least 62 children have died, allegedly after receiving a vaccination. The victims' parents blamed the dengue vaccine for the deaths of their children.[34]

• Official website